Standard of Care (SoC) ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
85	特発性間質性肺炎	1

85. 特発性間質性肺炎

---

臨床試験数 : 598 /  薬物数 : 435 - (DrugBank : 116) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 210

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03287414 (ClinicalTrials.gov)	December 20, 2017	12/9/2017	Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis	A Subject-, Investigator-, and Sponsor-blinded, Randomized, Placebo-controlled, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: VAY736;Drug: Placebo;Drug: Standard of Care (SoC)	Novartis Pharmaceuticals	NULL	Terminated	40 Years	80 Years	All	30	Phase 2	United States;Canada;Germany;Ireland;Italy;United Kingdom;France